228 related articles for article (PubMed ID: 20425434)
1. New and old prognostic factors in polycythemia vera.
Passamonti F
Curr Hematol Malig Rep; 2009 Jan; 4(1):19-24. PubMed ID: 20425434
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
3. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Pieri L; Rotunno G; Gisslinger H; Gisslinger B; Müllauer L; Finazzi G; Carobbio A; Gianatti A; Ruggeri M; Nichele I; D'Amore E; Rambaldi A; Tefferi A
Blood; 2012 Mar; 119(10):2239-41. PubMed ID: 22246040
[TBL] [Abstract][Full Text] [Related]
4. Correlative study between the JAK2V617F mutation and thrombosis in patients with myeloproliferative neoplasm.
Li ZC; Fu HJ; Wang ZM; Yang S; Xu HZ
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706633
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
7. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations.
Barraco D; Cerquozzi S; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Blood Cancer J; 2017 Mar; 7(3):e538. PubMed ID: 28282034
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of the quantification of JAK2V617F allele burden in classical Ph-negative myeloproliferative neoplasms].
Kerguelén Fuentes AE; Hernández-Maraver D; Lombardia L; Canales Albendea MA; Rodriguez de la Rúa A
Med Clin (Barc); 2012 Oct; 139(9):373-8. PubMed ID: 22743278
[TBL] [Abstract][Full Text] [Related]
11. Do we know more about essential thrombocythemia because of JAK2V617F?
Harrison C
Curr Hematol Malig Rep; 2009 Jan; 4(1):25-32. PubMed ID: 20425435
[TBL] [Abstract][Full Text] [Related]
12. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia.
Vannucchi AM
Intern Emerg Med; 2010 Jun; 5(3):177-84. PubMed ID: 19789961
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
[TBL] [Abstract][Full Text] [Related]
14. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.
Bertozzi I; Bogoni G; Biagetti G; Duner E; Lombardi AM; Fabris F; Randi ML
Ann Hematol; 2017 Aug; 96(8):1297-1302. PubMed ID: 28585070
[TBL] [Abstract][Full Text] [Related]
15. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
16. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
[TBL] [Abstract][Full Text] [Related]
19. Masked polycythemia vera (mPV): results of an international study.
Barbui T; Thiele J; Gisslinger H; Finazzi G; Carobbio A; Rumi E; Luigia Randi M; Bertozzi I; Vannucchi AM; Pieri L; Carrai V; Gisslinger B; Müllauer L; Ruggeri M; Rambaldi A; Tefferi A
Am J Hematol; 2014 Jan; 89(1):52-4. PubMed ID: 23996471
[TBL] [Abstract][Full Text] [Related]
20. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera.
Triguero A; Pedraza A; Pérez-Encinas M; Mata-Vázquez MI; Vélez P; Fox L; Gómez-Calafat M; García-Delgado R; Gasior M; Ferrer-Marín F; García-Gutiérrez V; Angona A; Gómez-Casares MT; Cuevas B; Martínez C; Pérez R; Raya JM; Guerrero L; Murillo I; Bellosillo B; Hernández-Boluda JC; Sanz C; Álvarez-Larrán A;
Ann Hematol; 2022 Oct; 101(10):2231-2239. PubMed ID: 36042023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
